Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Junko Tanizaki(Kindai University), Kazuhiko Nakagawa(Dana-Farber Cancer Institute), Kazuko Sakai(Ochanomizu University), Hidetoshi Hayashi(Kindai University Sakai Hospital), Erina Hatashita(National Hospital Organization), Takafumi Okabe(Dana-Farber Cancer Institute), Kiyoko Kuwata(National Hospital Organization), Isamu Okamoto(Kyushu University), Hiroyasu Kaneda(Kindai University), Haruka Yamaguchi(Nippon Dental University), Ken Takezawa(Dana-Farber Cancer Institute), Kaoru Tanaka(Kindai University), Kazuto Nishio(Kindai University)
Cited by 156
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k